GSK-3β and memory formation

Frontiers in Molecular Neuroscience

Volumn , Issue APRIL, 2012, Pages

  Takashima, Akihiko ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Aging; Alzheimer's disease; Memory formation; Memory impairment; Tau

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN REGION; CAUSAL ATTRIBUTION; CELL LOSS; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE CELL; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPSE; TREATMENT DURATION;

EID: 85197334850     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2012.00047     Document Type: Review

References (61)

1. Beaulieu, J. M., Del'Guidice, T., Sot-nikova, T. D., Lemasson, M., and Gainetdinov, R. R. (2011). Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front. Mol. Neurosci. 4:38. doi: 10.3389/ fnmol.2011.00038
2. Biedenkapp, J. C., and Rudy, J. W. (2004). Context memories and reactivation: constraints on the reconsolidation hypothesis. Behav. Neurosci. 118, 956-964.
3. Braak, H., and Braak, E. (1990). Neurofibrillary changes confined to the entorhinal region and an abundance of cortical amyloid in cases of prese-nile and senile dementia. Acta Neu-ropathol. 80, 479-486.
4. Braak, H., and Braak, E. (1996). Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165, 3-12.
5. Bradley, C. A., Peineau, S., Taghibiglou, C., Nicolas, C. S., Whitcomb, D. J., Bortolotto, Z. A., Kaang, B. K., Cho, K., Wang, Y. T., and Collingridge, G. L. (2012). A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 5:13. doi: 10.3389/fnmol. 2012.00013
6. de Barreda, E. G, Perez, M., Gomez Ramos, P., De Cristobal, J., Martin-Maestro, P., Moran, A., Dawson, H. N., Vitek, M. P., Lucas, J. J., Hernandez, F., and Avila, J. (2010). Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol. Dis. 37, 622-629.
7. Diamond, D. M., Park, C. R., Campbell, A. M., and Woodson, J. C. (2005). Competitive interactions between endogenous LTD and LTP in the hippocampus underlie the storage of emotional memories and stress-induced amnesia. Hippocam-pus15, 1006-1025.
8. Dudai, Y., and Eisenberg, M. (2004). Rites of passage of the engram: reconsolidation and the lingering consolidation hypothesis. Neuron 44, 93-100.
9. Dunn, N., Holmes, C., and Mullee, M. (2005). Does lithium therapy protect against the onset of dementia? Alzheimer Dis. Assoc. Disord. 19, 20-22.
10. Eisenberg, M., Kobilo, T., Berman, D. E., and Dudai, Y. (2003). Stability of retrieved memory: inverse correlation with trace dominance. Science 301, 1102-1104.
11. Eldar-Finkelman, H., and Martinez, A. (2011). GSK-3 inhibitors: preclini-cal and clinical focus on CNS. Front. Mol. Neurosci. 4:32. doi: 10.3389/ fnmol.2011.00032
12. Engel, T., Goni-Oliver, P., Lucas, J. J., Avila, J., and Hernandez, F. (2006). Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445-1455.
13. Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., and Gat-taz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry 198, 351-356.
14. Freland, L., and Beaulieu, J. M. (2012). Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci. 5:14. doi: 10.3389/fnmol.2012.00014
15. Goate, A., and Hardy, J. (2011). Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. Suppl. 1, 3-8.
16. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., and Hyman, B. T. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24.
17. Gotz, J., and Ittner, L. M. (2008). Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544.
18. Gould, T. D., Picchini, A. M., Einat, H., and Manji, H. K. (2006). Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets 7, 1399-1409.
19. Hampel, H., Ewers, M., Burger, K., Annas, P., Mortberg, A., Bogst-edt, A., Frolich, L., Schroder, J., Schonknecht, P., Riepe, M. W., Kraft, I., Gasser, T., Leyhe, T., Moller, H. J., Kurz, A., and Basun, H. (2009). Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70, 922-931.
20. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
21. Hernandez, F., Borrell, J., Guaza, C., Avila, J., and Lucas, J. J. (2002). Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533.
22. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86-90.
23. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., Zotova, E., and Nicoll, J. A. (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223.
24. Hooper, C., Markevich, V., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernandez, F., Anderton, B., Rosen-blum, K., Bliss, T., Cooke, S. F., Avila, J., Lucas, J. J., Giese, K. P., Stephenson, J., andLovestone, S. (2007). Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25, 81-86.
25. Hoshi, M., Sato, M., Kondo, S., Takashima, A., Noguchi, K., Taka-hashi, M., Ishiguro, K., and Imahori, K. (1995). Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. J. Biochem. 118, 683-685.
26. Ishiguro, K., Ihara, Y., Uchida, T., and Imahori, K. (1988). A novel tubulin-dependent protein kinase forming a paired helical filament epitope on tau. J. Biochem. 104, 319-321.
27. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., and Imahori, K. (1993). Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167-172.
28. Kang, H., Sun, L. D., Atkins, C. M., Soderling, T. R., Wilson, M. A., and Tonegawa, S. (2001). An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory. Cell 106, 771-783.
29. Kimura, T., Fukuda, T., Sahara, N., Yamashita, S., Murayama, M., Mizoroki, T., Yoshiike, Y., Lee, B., Sotiropoulos, I., Maeda, S., and Takashima, A. (2010). Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285, 38692-38699.
30. Kimura, T., Yamashita, S., Fukuda, T., Park, J. M., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., and Takashima, A. (2007). Hyperphos-phorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J. 26, 5143-5152.
31. Kimura, T., Yamashita, S., Nakao, S., Park, J. M., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., and Takashima, A. (2008). GSK-3ß is required for memoryreconsolidation in adult brain. PLoS ONE 3, e3540. doi: 10.1371/journal.pone.0003540
32. Klein, P. S., and Melton, D. A. (1996). A molecular mechanism for the effect oflithium on development. Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459.
33. Lee, J. L. C., Milton, A. L., and Everitt, B. J. (2006). Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J. Neurosci. 26, 10051-10056.
34. Leroy, K., Ando, K., Heraud, C., Yil-maz, Z., Authelet, M., Boeynaems, J. M., Buee, L., De Decker, R., and Brion, J. P. (2010). Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J. Alzheimers Dis. 19, 705-719.
35. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBOJ. 20, 27-39.
36. MacAulay, K., Doble, B. W., Patel, S., Hansotia, T., Sinclair, E. M., Drucker, D. J., Nagy, A., and Woodgett, J. R. (2007). Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab. 6, 329-337.
37. Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Murayama, S., Ikai, A., and Takashima, A. (2007). Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861.
38. Masliah, E., Ellisman, M., Carragher, B., Mallory, M., Young, S., Hansen, L., Deteresa, R., and Terry, R. D. (1992). Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J. Neuropathol. Exp. Neurol. 51, 404-414.
39. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., and Ihara, Y. (1995). Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829.
40. Morris, R. G. M., Inglis, J., Ainge, J. A., Olverman, H. J., Tulloch, J., Dudai, Y., and Kelly, P. A. T. (2006). Memory reconsolidation: sensitivity of spatial memoryto inhibition of protein synthesis in dorsal hippocampus during encoding and retrieval. Neuron 50, 479-489.
41. Nader, K., Schafe, G. E., and Ledoux, J. E. (2000). The labile nature of consolidation theory. Nat. Rev. Neurosci. 1, 216-219.
42. Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., Matthews, P., Isaac, J. T., Bortolotto, Z.A., Wang, Y. T., and Collingridge, G. L. (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703-717.
43. Poissonnet, A., Henry-Feugeas, M. C., Drunat, O., Wolmark, Y., Delpierre, S., and Koskas, P. (2012). Evaluation of visual recognition memory for the early diagnosis of Alzheimer's disease in patients over 75 years. Rev. Neurol. doi: 10.1016/j.neurol.2011.11.004 [Epub ahead of print].
44. Polter, A. M., and Li, X. (2011). Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission. Front. Mol. Neurosci. 4:31. doi: 10.3389/fnmol. 2011.00031
45. Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., Mcgowan, E., Santacruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., Hutton, M., and Ashe, K. H. (2005). Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse modelofhumantauopathy(P301L). J. Neurosci. 25, 10637-10647.
46. Riccio, D. C., Moody, E. W., and Millin, P. M. (2002). Reconsolidation reconsidered. Integr. Physiol. Behav. Sci. 37, 245-253.
47. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q., and Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
48. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., Deture, M., Rams-den, M., Mcgowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mari-ash, A., Kuskowski, M., Hyman, B., Hutton, M., and Ashe, K. H. (2005). Tau suppression in a neurode-generative mouse model improves memory function. Science 309, 476-481.
49. Sato, S., Tatebayashi, Y., Akagi, T., Chui, D. H., Murayama, M., Miyasaka, T., Planel, E., Tanemura, K., Sun, X., Hashikawa, T., Yoshioka, K., Ishig-uro, K., and Takashima, A. (2002). Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 277, 42060-42065.
50. Selkoe, D. J. (1986). Altered structural proteins in plaques and tangles: what do they tell us about the biology of Alzheimer's disease? Neurobiol. Aging 7, 425-432.
51. Sereno, L., Coma, M., Rodriguez, M., Sanchez-Ferrer, P., Sanchez, M. B., Gich, I., Agullo, J. M., Perez, M., Avila, J., Guardia-Laguarta, C., Clarimon, J., Lleo, A., and Gomez-Isla, T. (2009). A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367.
52. Spires, T. L., Orne, J. D., Santacruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., and Hyman, B. T. (2006). Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168, 1598-1607.
53. Takashima, A. (2008). Hyperphospho-rylated tau is a cause of neuronal dysfunction in tauopathy. J. Alzheimers Dis. 14, 371-375.
54. Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., and Imahori, K. (1996). Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivationofphosphatidylinositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 203, 33-36.
55. Takashima, A., Noguchi, K., Sato, K., Hoshino, T., and Imahori, K. (1993). Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90, 7789-7793.
56. Tandon, A., Rogaeva, E., Mullan, M., and St George-Hyslop, P. H. (2000). Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr. Opin. Neurol. 13, 377-384.
57. Tsien, J. Z., Huerta, P. T., and Tone-gawa, S. (1996). The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87, 1327-1338.
58. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., andSelkoe, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
59. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., and Ashe, K. H. (2002). The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867.
60. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 8, 2431-2438.
61. Zhang, X., Heng, X., Li, T., Li, L., Yang, D., Du, Y., Doody, R. S., and Le, W. (2011). Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J. Alzheimers Dis. 24, 739-749.